Atyr PHARMA (ATYR) Competitors $3.08 +0.05 (+1.65%) (As of 12/17/2024 ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainSEC FilingsShort InterestTrends ATYR vs. COLL, SEPN, BCAX, ZYME, GYRE, PSTX, PAHC, COGT, NUVB, and AVBPShould you be buying Atyr PHARMA stock or one of its competitors? The main competitors of Atyr PHARMA include Collegium Pharmaceutical (COLL), Septerna (SEPN), Bicara Therapeutics (BCAX), Zymeworks (ZYME), Gyre Therapeutics (GYRE), Poseida Therapeutics (PSTX), Phibro Animal Health (PAHC), Cogent Biosciences (COGT), Nuvation Bio (NUVB), and ArriVent BioPharma (AVBP). These companies are all part of the "pharmaceutical products" industry. Atyr PHARMA vs. Collegium Pharmaceutical Septerna Bicara Therapeutics Zymeworks Gyre Therapeutics Poseida Therapeutics Phibro Animal Health Cogent Biosciences Nuvation Bio ArriVent BioPharma Atyr PHARMA (NASDAQ:ATYR) and Collegium Pharmaceutical (NASDAQ:COLL) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their profitability, community ranking, valuation, dividends, institutional ownership, risk, earnings, analyst recommendations and media sentiment. Is ATYR or COLL more profitable? Collegium Pharmaceutical has a net margin of 14.78% compared to Atyr PHARMA's net margin of 0.00%. Collegium Pharmaceutical's return on equity of 104.67% beat Atyr PHARMA's return on equity.Company Net Margins Return on Equity Return on Assets Atyr PHARMAN/A -79.44% -59.16% Collegium Pharmaceutical 14.78%104.67%18.38% Do analysts prefer ATYR or COLL? Atyr PHARMA currently has a consensus price target of $19.25, suggesting a potential upside of 525.00%. Collegium Pharmaceutical has a consensus price target of $42.60, suggesting a potential upside of 37.86%. Given Atyr PHARMA's stronger consensus rating and higher possible upside, analysts clearly believe Atyr PHARMA is more favorable than Collegium Pharmaceutical.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Atyr PHARMA 0 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 3.00Collegium Pharmaceutical 0 Sell rating(s) 2 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.60 Which has stronger valuation & earnings, ATYR or COLL? Collegium Pharmaceutical has higher revenue and earnings than Atyr PHARMA. Atyr PHARMA is trading at a lower price-to-earnings ratio than Collegium Pharmaceutical, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAtyr PHARMA$235K1,100.18-$50.39M-$0.94-3.28Collegium Pharmaceutical$599.25M1.66$48.15M$2.3213.32 Does the MarketBeat Community favor ATYR or COLL? Collegium Pharmaceutical received 376 more outperform votes than Atyr PHARMA when rated by MarketBeat users. However, 100.00% of users gave Atyr PHARMA an outperform vote while only 65.25% of users gave Collegium Pharmaceutical an outperform vote. CompanyUnderperformOutperformAtyr PHARMAOutperform Votes9100.00% Underperform VotesNo VotesCollegium PharmaceuticalOutperform Votes38565.25% Underperform Votes20534.75% Does the media refer more to ATYR or COLL? In the previous week, Atyr PHARMA had 1 more articles in the media than Collegium Pharmaceutical. MarketBeat recorded 5 mentions for Atyr PHARMA and 4 mentions for Collegium Pharmaceutical. Collegium Pharmaceutical's average media sentiment score of 1.63 beat Atyr PHARMA's score of 0.69 indicating that Collegium Pharmaceutical is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Atyr PHARMA 1 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Collegium Pharmaceutical 3 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Do insiders and institutionals hold more shares of ATYR or COLL? 61.7% of Atyr PHARMA shares are held by institutional investors. 3.7% of Atyr PHARMA shares are held by insiders. Comparatively, 4.0% of Collegium Pharmaceutical shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth. Which has more volatility & risk, ATYR or COLL? Atyr PHARMA has a beta of 1.07, indicating that its share price is 7% more volatile than the S&P 500. Comparatively, Collegium Pharmaceutical has a beta of 0.8, indicating that its share price is 20% less volatile than the S&P 500. SummaryCollegium Pharmaceutical beats Atyr PHARMA on 10 of the 18 factors compared between the two stocks. Ad Porter & CompanyMusk threatens Liberal’s fake “energy crisis”Elon Musk has just exposed the “energy grift” of America in a recent tweet to his platform, X. And people are slowly starting to wake up to the Deep State’s lies.To get the full details on the fake “energy crisis” of America, watch this now Get Atyr PHARMA News Delivered to You Automatically Sign up to receive the latest news and ratings for ATYR and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ATYR vs. The Competition Export to ExcelMetricAtyr PHARMABiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$258.54M$2.98B$5.19B$9.32BDividend YieldN/A1.85%4.78%4.06%P/E Ratio-3.2846.24128.2217.54Price / Sales1,100.18420.891,259.00139.66Price / CashN/A182.1341.2237.95Price / Book2.003.924.884.92Net Income-$50.39M-$42.03M$119.69M$225.78M7 Day Performance-2.84%-3.37%16.64%-1.56%1 Month Performance2.33%7.95%16.32%6.68%1 Year PerformanceN/A21.00%35.37%22.48% Atyr PHARMA Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ATYRAtyr PHARMA2.6077 of 5 stars$3.08+1.7%$19.25+525.0%N/A$254.34M$235,000.00-3.2856COLLCollegium Pharmaceutical3.9712 of 5 stars$30.64+1.8%$42.60+39.0%+4.3%$988.14M$599.25M12.97210News CoveragePositive NewsSEPNSepterna1.7246 of 5 stars$21.60-3.5%$43.67+102.2%N/A$959.04MN/A0.00N/ABCAXBicara TherapeuticsN/A$17.53+0.2%$43.00+145.3%N/A$953.91MN/A0.0032ZYMEZymeworks3.0526 of 5 stars$13.74+9.2%$18.83+37.1%+46.9%$946.41M$76.01M-9.25290Analyst UpgradePositive NewsGYREGyre Therapeutics0.3745 of 5 stars$10.03+4.0%N/A-54.6%$938.02M$105.03M0.0040News CoverageGap UpPSTXPoseida Therapeutics3.7029 of 5 stars$9.50-0.1%$9.50+193.2%$928.82M$64.70M-15.10260PAHCPhibro Animal Health4.1953 of 5 stars$22.76+0.4%$19.00-16.5%+97.9%$921.85M$1.05B52.561,940Analyst ForecastNews CoverageCOGTCogent Biosciences2.265 of 5 stars$8.22+0.9%$14.83+80.5%+67.8%$907.98MN/A-3.2980Short Interest ↑NUVBNuvation Bio1.9641 of 5 stars$2.67+2.3%$6.60+147.2%+99.6%$898.64MN/A0.0060AVBPArriVent BioPharma1.1598 of 5 stars$26.66-0.2%$36.80+38.0%N/A$898.36MN/A0.0040Short Interest ↑Positive News Related Companies and Tools Related Companies Collegium Pharmaceutical Alternatives Septerna Alternatives Bicara Therapeutics Alternatives Zymeworks Alternatives Gyre Therapeutics Alternatives Poseida Therapeutics Alternatives Phibro Animal Health Alternatives Cogent Biosciences Alternatives Nuvation Bio Alternatives ArriVent BioPharma Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:ATYR) was last updated on 12/18/2024 by MarketBeat.com Staff From Our PartnersTrump’s Secret Manhattan ProjectOn January 20, a whole new Manhattan Project is set to begin: Trump’s Manhattan Project. Folks, I just s...Banyan Hill Publishing | SponsoredHow this >10-cent coin is going to outperform Bitcoin Chris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | SponsoredSeeing is believing… Today, I want to share all the details with you… and show you how to leverage this incredible wealth-building ...Porter & Company | SponsoredUncover the Top Gold Stock of the Bull MarketGold Stocks Are Surging—Is West Red Lake Gold Mines Your Next Profit Play?Huge Alerts | SponsoredPlease don’t take this warning lightly…Something huge is about to hit the stock market. Wall St. legend Louis Navellier calls it: "The most signif...InvestorPlace | SponsoredWe recommended Palantir in 2021, now we’re recommending this...My research indicates there is only one investment that can meet AI's unprecedented demand for energy.Behind the Markets | SponsoredMissed Nvidia? Buy Elon Musk’s “Silent Partner”In February 2016, when almost nobody was talking about artificial intelligence… I picked Nvidia as one of my f...Brownstone Research | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Atyr PHARMA INC Please log in to your account or sign up in order to add this asset to your watchlist. Share Atyr PHARMA With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free ATYR Stock Alerts